Patents by Inventor Andrew M. Blumenfeld

Andrew M. Blumenfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BOTULINUM TOXIN TREATMENTS OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
    Publication number: 20180369348
    Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 27, 2018
    Inventor: Andrew M. Blumenfeld
  • Injection paradigm for administration of botulinum toxins
    Patent number: 10111938
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: October 30, 2018
    Assignee: Allergan, Inc.
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Botulinum toxin treatments of neurological and neuropsychiatric disorders
    Patent number: 10064921
    Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: September 4, 2018
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Suture Line Administration Technique Using Botulinum Toxins
    Publication number: 20180078622
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 22, 2018
    Inventor: Andrew M. Blumenfeld
  • TREATMENT OF PSYCHOLOGICAL TRAUMA
    Publication number: 20180000909
    Abstract: The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 4, 2018
    Inventors: Kenton B. Abel, Andrew M. Blumenfeld
  • Suture line administration technique using botulinum toxins
    Patent number: 9827297
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 28, 2017
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Treatment of psychological trauma
    Patent number: 9764009
    Abstract: The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: September 19, 2017
    Assignee: Allergan, Inc.
    Inventors: Kenton B. Abel, Andrew M. Blumenfeld
  • BOTULINUM TOXIN TREATMENTS OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
    Publication number: 20170173123
    Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
    Type: Application
    Filed: March 2, 2017
    Publication date: June 22, 2017
    Inventor: Andrew M. Blumenfeld
  • INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS
    Publication number: 20160263202
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Application
    Filed: March 11, 2016
    Publication date: September 15, 2016
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Suture Line Administration Technique Using Botulinum Toxins
    Publication number: 20160151468
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Application
    Filed: February 1, 2016
    Publication date: June 2, 2016
    Inventor: Andrew M. Blumenfeld
  • Suture line administration technique using botulinum toxins
    Patent number: 9248168
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: February 2, 2016
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Botulinum toxin treatment of anxiety and bipolar disorders
    Patent number: 9238061
    Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: January 19, 2016
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Method for treatment of esophageal spasm
    Patent number: 8992941
    Abstract: The present invention relates to methods of treating esophageal spasms using botulinum toxins.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: March 31, 2015
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Targeted delivery of botulinum toxin to the sphenopalatine ganglion
    Patent number: 8846622
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: September 30, 2014
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • BOTULINUM TOXIN TREATMENTS OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
    Publication number: 20140205590
    Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
    Type: Application
    Filed: April 8, 2014
    Publication date: July 24, 2014
    Applicant: ALLERGAN, INC.
    Inventor: Andrew M. Blumenfeld
  • Botulinum toxin treatments of neurological and neuropsychiatric disorders
    Patent number: 8734810
    Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: May 27, 2014
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • METHOD FOR TREATMENT OF AUTONOMIC NERVOUS SYSTEM DISORDERS
    Publication number: 20140140983
    Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment of autonomic nervous system disorders such as irritable bowel syndrome. The neurotoxin is delivered to target the sympathetic ganglion. Exemplary delivery is carried out by way of injection.
    Type: Application
    Filed: July 6, 2012
    Publication date: May 22, 2014
    Applicant: ALLERGAN, INC.
    Inventor: Andrew M. Blumenfeld
  • Botulinum toxin compositions and methods
    Patent number: 8697066
    Abstract: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: April 15, 2014
    Assignee: Allergan, Inc.
    Inventors: Franklin D. Gaylis, Andrew M. Blumenfeld
  • Botulinum toxin treatments of Depression
    Publication number: 20140099298
    Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.
    Type: Application
    Filed: November 21, 2013
    Publication date: April 10, 2014
    Inventor: Andrew M. Blumenfeld
  • Suture line Administration Technique using Botulinum Toxins
    Publication number: 20140079687
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Application
    Filed: November 21, 2013
    Publication date: March 20, 2014
    Inventor: Andrew M. Blumenfeld